Genetic and phenotypic overlap of specific obsessive-compulsive and attention-deficit/hyperactive subtypes with Tourette syndrome. [electronic resource]
By: Contributor(s): Producer: 20180801Description: 279-293 p. digitalISSN:- 1469-8978
Publication Type: Journal Article
There are no comments on this title.
-
61
Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer.
by Steyerberg, E W -
62
Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
by McCaffrey, J A -
63
Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.
by Bajorin, D F -
64
Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors.
by Motzer, R J -
65
Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.
by Bajorin, D F -
66
Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
by Dodd, P M -
67
Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors.
by Seidman, A D -
68
Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.
by Bajorin, D F -
69
The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors.
by Motzer, R J -
70
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
by Dodd, P M -
71
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center.
by Puc, H S -
72
Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma.
by Bajorin, D F -
73
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
by Rosenberg, J E -
74
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
by Bajorin, D F -
75
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.
by Sarkis, A S -
76
Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
by Law, T M -
77
Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.
by Motzer, R J -
78
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.
by Seidman, A D -
79
A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.
by Ilson, D H -
80
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.
by Motzer, R J
Genetic and phenotypic overlap of specific obsessive-compulsive and attention-deficit/hyperactive subtypes with Tourette syndrome.
APA
Hirschtritt M. E., Darrow S. M., Illmann C., Osiecki L., Grados M., Sandor P., Dion Y., King R. A., Pauls D., Budman C. L., Cath D. C., Greenberg E., Lyon G. J., Yu D., McGrath L. M., McMahon W. M., Lee P. C., Delucchi K. L., Scharf J. M. & Mathews C. A. (20180801). Genetic and phenotypic overlap of specific obsessive-compulsive and attention-deficit/hyperactive subtypes with Tourette syndrome. : Psychological medicine.
Chicago
Hirschtritt M E, Darrow S M, Illmann C, Osiecki L, Grados M, Sandor P, Dion Y, King R A, Pauls D, Budman C L, Cath D C, Greenberg E, Lyon G J, Yu D, McGrath L M, McMahon W M, Lee P C, Delucchi K L, Scharf J M and Mathews C A. 20180801. Genetic and phenotypic overlap of specific obsessive-compulsive and attention-deficit/hyperactive subtypes with Tourette syndrome. : Psychological medicine.
Harvard
Hirschtritt M. E., Darrow S. M., Illmann C., Osiecki L., Grados M., Sandor P., Dion Y., King R. A., Pauls D., Budman C. L., Cath D. C., Greenberg E., Lyon G. J., Yu D., McGrath L. M., McMahon W. M., Lee P. C., Delucchi K. L., Scharf J. M. and Mathews C. A. (20180801). Genetic and phenotypic overlap of specific obsessive-compulsive and attention-deficit/hyperactive subtypes with Tourette syndrome. : Psychological medicine.
MLA
Hirschtritt M E, Darrow S M, Illmann C, Osiecki L, Grados M, Sandor P, Dion Y, King R A, Pauls D, Budman C L, Cath D C, Greenberg E, Lyon G J, Yu D, McGrath L M, McMahon W M, Lee P C, Delucchi K L, Scharf J M and Mathews C A. Genetic and phenotypic overlap of specific obsessive-compulsive and attention-deficit/hyperactive subtypes with Tourette syndrome. : Psychological medicine. 20180801.